Searching for smart, safe news you can TRUST?
Support safe, smart, REAL journalism. Sign up for our Axios AM & PM newsletters and get smarter, faster.
Searching for smart, safe news you can TRUST?
Support safe, smart, REAL journalism. Sign up for our Axios AM & PM newsletters and get smarter, faster.
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul
Tampa-St. Petersburg news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg
An FDA advisory committee yesterday voted to recommend that Makena, a treatment to prevent women from having a preterm birth, be withdrawn from the market after a study found that it's ineffective, the Wall Street Journal reports.
Backdrop: The FDA approved the drug in 2011, but required a follow-up study. That study came out last week and found that the drug — which has become the standard treatment — doesn't decrease recurrent preterm births.
What they're saying: "At the end of the day we want to be giving pregnant women medications that work and help them and their babies," Adam Urato, chief of maternal-fetal medicine at MetroWest Medical Center in Framingham, Mass., told the Journal. "This drug doesn't work."
Go deeper: When an expensive drug turns out to be a dud